RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

Special systems were developed for response assessment of immunooncology drugs. The role and benefits of particular system in assessing the efficacy of different immunotherapy methods are not clear yet. The objective of this study is to compare the responses on ipilimab (IPI) or dendritic cell vacci...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: A. V. Novik, E. V. Yaremenko, E. M. Anokhina, T. L. Nehaeva, A. I. Semenova, D. Kh. Latipova, S. A. Protsenko, I. A. Baldueva
Format: Artigo
Jezik:Russo
Izdano: Tomsk National Research Medical Center of the Russian Academy of Sciences 2019-09-01
Serija:Sibirskij Onkologičeskij Žurnal
Teme:
melanoma
ipilimumab
dendritic cell vaccines
recist 1.1
irrc
response assessment
immunotherapy
Online dostop:https://www.siboncoj.ru/jour/article/view/1136
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki